by Joanne Hedin | Nov 15, 2024 | Uncategorized
FCTDI is pleased to announce that it has been awarded a Phase I Contract SBIR from NIAID/NIH entitled “Combinations of Oral Antibiotics to Treat Syphilis”....
by Joanne Hedin | Nov 11, 2024 | Uncategorized
Allen Reitz, CEO of FCTDI, has been awarded the 2nd Annual Timothy E. Block Biotech Impact Award...
by Joanne Hedin | Aug 2, 2024 | Uncategorized
Fox Chase Therapeutics Discovery, Inc. (formerly known as Fox Chase Chemical Diversity Center) Announces That It Has Been Awarded a Phase II STTR grant from the National Institutes of Health (NIAID) with Prof. Robert Ricciardi of the University of Pennsylvania...
by fctdiadmin | Jun 5, 2023 | Uncategorized
Fox Chase Therapeutics Discovery Inc (formerly known as Fox Chase Chemical Diversity Center) Announces That a New Drug Application Was Submitted to the FDA for Troriluzole by Biohaven Pharmaceuticals Doylestown, PA. June 5, 2023 – Fox Chase Therapeutics...
by Kelley Tracy | Apr 11, 2023 | Uncategorized
Fox Chase Therapeutics Discovery Inc (formerly known as Fox Chase Chemical Diversity Center) Announces That It Has Been Awarded a Phase II SBIR From the NIH (NIAID) entitled “Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle”...
by Kelley Tracy | Feb 3, 2023 | Uncategorized
Fox Chase Therapeutics Discovery Inc (formerly known as Fox Chase Chemical Diversity Center) Announces That a Tau Self-Association Inhibitor Designed and Prepared in its Laboratories Has Achieved First in Human Dosing Doylestown, PA. February 3, 2023 – FCTDI (formerly...
